The present invention provides novel compounds (e.g., compounds of Formula I) which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels. ##STR00001##

The present disclosure provides polymerizable monomers which may be used as reactive diluents in additive manufacturing. The polymerizable monomers may have low vapor pressures and may be compatible with a range of low glass transition temperature oligomers.

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof,

##STR00001##

Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compound of Formula (I).

This invention discloses cannabinoids linked with polyethylene glycol chains. The cannabinoid-polyethylene glycol chain molecules have one, two, or more cannabinoids linked with one, two, or more polyethylene glycol chains. Each cannabinoid-polyethylene glycol chain molecule may have one kind of cannabinoid or multiple kinds of cannabinoid. Methods to make these cannabinoid-polyethylene glycol linked chains are disclosed.

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

The invention relates to a method for producing styrene monomers by the depolymerisation of polystyrene in the presence of foreign polymers, such as polyolefins. Said method comprises the following steps: a) introducing a polymer composition (A) containing: I) 10 to 99.5% by weight, based on the polymer composition (A), of polystyrene (I); and II) 0.1 to 89.9% by weight of polyolefin (II); and/or III) 0.1 to 4.9% by weight of acrylonitrile-based polymer (III); and/or IV) 0.1 to 4.9% by weight of polyester (IV), into the reaction zone (R) of a pyrolysis reactor (P); b) thermal cracking the polystyrene contained in the polymer composition (A) in the reaction zone (R) of the pyrolysis reactor (P) at a temperature of between 400-1000° C., c) removing the product mixture (G) obtained from the reaction zone (R), d) cooling of the product mixture (G), and e) separating the styrene monomers from the further components.

Disclosed are a salt represented by formula (I), an acid generator, and a resist composition comprising the same:

##STR00001##

wherein R.sup.1 and R.sup.2 each represent a hydroxy group, *—O—R.sup.10, *—O-L.sup.10-CO—O—R.sup.10; L.sup.10 represents an alkanediyl group; R.sup.10 represents an acid-labile group; R.sup.4, R.sup.5, R.sup.7 and R.sup.8 each represent a halogen atom, a haloalkyl group or a hydrocarbon group; A.sup.1 and A.sup.2 each represent a hydrocarbon group, the hydrocarbon group may have a substituent, and —CH.sub.2— included in the hydrocarbon group may be replaced by —O—, —CO—, —S— or —SO.sub.2—; m1 represents an integer of 1 to 5, m2 and m8 represent an integer of 0 to 5, m4, m5 and m7 represent an integer of 0 to 4, 1≤m1+m7≤5, 0≤m2+m8≤5; and AI.sup.− represents an organic anion.

A photosensitive layer of an electrophotographic photosensitive member is a single layer and contains a charge generating material, a hole transport material, a first electron transport material, a second electron transport material, and a binder resin. The binder resin includes a polyarylate resin. The polyarylate resin includes repeating units (1), (2), (3), and (4).

##STR00001##

A percentage of the number of repeats of the repeating unit (3) relative to the total of the number of repeats of the repeating units (1) and the number of repeats of the repeating unit (3) is greater than 0% and less than 20%. The first electron transport material includes a compound represented by formula (A15) or (A16).

##STR00002##

The second electron transport material includes a compound represented by formula (B10), (B11), (B12), (B13), or (B14)

##STR00003##

A pharmaceutical composition containing an effective amount of cannabidiol (CBD) for use in treating or preventing a heart condition, along with related methods and uses. The heart conditions include heart failure, acute myocarditis, toxicity caused by anti-cancer therapies, acute pericarditis, cardiac sarcoidosis, inflammatory cardiomyopathy, and atherosclerosis and related uses and methods. The disclosure shows CBD to be effective in (i) reducing cardiac hypertrophy; (ii) reducing cardiac fibrosis; (iii) reducing the level of BNP; (iv) reducing the level of cytokine IL1β; (v) reducing the level of cytokine IL6; (vi) reducing the level of CD69; (vii) increasing the level of cytokine IL10, and (viii) combinations thereof. The composition is preferably adapted for parenteral administration.

The disclosure provides, inter alia, alpha-5 beta-1 inhibitors, pharmaceutical compositions comprising alpha-5 beta-1 inhibitors, methods for treating diseases using alpha-5 beta-1 inhibitors, and processes for making alpha-5 beta-1 inhibitors.